The A1 astrocyte paradigm: New avenues for pharmacological intervention in neurodegeneration

Volume: 34, Issue: 7, Pages: 959 - 969
Published: May 28, 2019
Abstract
We recently demonstrated that NLY01, a novel glucagon‐like peptide‐1 receptor agonist, exerts neuroprotective effects in two mouse models of PD in a glia‐dependent manner. NLY01 prevented microglia from releasing inflammatory mediators known to convert astrocytes into a neurotoxic A1 reactive subtype. Importantly, we provided evidence that this neuroprotection was not mediated by a direct action of NLY01 on neurons or astrocytes (e.g., by...
Paper Details
Title
The A1 astrocyte paradigm: New avenues for pharmacological intervention in neurodegeneration
Published Date
May 28, 2019
Volume
34
Issue
7
Pages
959 - 969
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.